| Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs B Gok Yavuz, G Gunaydin, ME Gedik, K Kosemehmetoglu, D Karakoc, ... Scientific reports 9 (1), 3172, 2019 | 231 | 2019 |
| Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial AO Kaseb, E Hasanov, HST Cao, L Xiao, JN Vauthey, SS Lee, BG Yavuz, ... The Lancet Gastroenterology & Hepatology 7 (3), 208-218, 2022 | 147 | 2022 |
| Origin and role of hepatic myofibroblasts in hepatocellular carcinoma BG Yavuz, RC Pestana, YI Abugabal, S Krishnan, J Chen, MM Hassan, ... Oncotarget 11 (13), 1186, 2020 | 39 | 2020 |
| Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma B Gok Yavuz, E Hasanov, SS Lee, YI Mohamed, MA Curran, EJ Koay, ... Journal of Hepatocellular Carcinoma, 1195-1207, 2021 | 24 | 2021 |
| A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ThymoQuinone formula (TQF) for treating outpatient SARS-CoV-2 H Bencheqroun, Y Ahmed, M Kocak, E Villa, C Barrera, M Mohiuddin, ... Pathogens 11 (5), 551, 2022 | 10 | 2022 |
| The effects of cancer‐associated fibroblasts obtained from atypical ductal hyperplasia on anti‐tumor immune responses. B Gok Yavuz, G Gunaydin, K Kosemehmetoglu, D Karakoc, F Ozgur, ... Breast Journal 24 (6), 2018 | 10 | 2018 |
| Serum IGF-1 scores and clinical outcomes in the phase III imbrave150 study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma AO Kaseb, Y Guan, B Gok Yavuz, AR Abbas, S Lu, E Hasanov, HC Toh, ... Journal of Hepatocellular Carcinoma, 1065-1079, 2022 | 5 | 2022 |
| Abstract CT224: Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big … S Arain, P Patel, K Sweiss, B Parkin, H Konig, G Calip, BG Yavuz, ... Cancer Research 81 (13_Supplement), CT224-CT224, 2021 | 2 | 2021 |
| Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis J Hwang, N Singh, M Braniecki, BG Yavuz, MM Tsoukas, JG Quigley British journal of haematology, 2021 | 2 | 2021 |
| The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma B Gok Yavuz, S Datar, S Chamseddine, YI Mohamed, M LaPelusa, ... Cancers 15 (19), 4875, 2023 | 1 | 2023 |
| Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection A Maen, B Gok Yavuz, YI Mohamed, A Esmail, J Lu, A Mohamed, AS Azmi, ... Frontiers in Pharmacology 15, 1291212, 2024 | | 2024 |
| Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable … MB LaPelusa, S Chamseddine, L Xiao, E Hasanov, P Bhosale, ... Journal of Clinical Oncology 42 (3_suppl), 561-561, 2024 | | 2024 |
| Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML S Houshyar, BG Yavuz, P Patel, N Mahmud, K Sweiss, I Khan, SL Saraf, ... Blood 140 (Supplement 1), 5957-5958, 2022 | | 2022 |
| 42 The role of tissue stiffness in predicting the immunotherapy response in hepatocellular carcinoma BG Yavuz, E Hasanov, L Xiao, M Yehia, S Lee, A Rashid, A Kaseb, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A49-A49, 2021 | | 2021 |
| Hematologic Predictors of Outcomes in Patients Undergoing Intensive Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia S Arain, E Shah, BG Yavuz, S Stettner, GS Calip, I Khan, P Patel, ... Blood 136 (Supplement 1), 39-40, 2020 | | 2020 |
| Meme Kanserinde, Normal Fibroblastlar ve Kanserle İlişkili Fibroblastların Monosit Çağrılması, Makrofaj Polarizasyonu ve İnvazyona Etkisi B Gök Yavuz Kanser Enstitüsü, 2018 | | 2018 |
Yehia I.Mohamed AbugabalMD, The University of Texas, MD Anderson cancer center, USA在 mdanderson.org 的电子邮件经过验证
